e-learning
resources
London 2016
Tuesday, 06.09.2016
Preclinical pharmacology: drug targets and mechanisms of action
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effect of oligomeric proanthocyanidin on airway microenvironment in asthma
Xiaoning Zeng (Nanjing, China), Xiaoning Zeng, Yuan Ma, Hao Gu, Yihang Gu, Mao Huang
Source:
International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Session:
Preclinical pharmacology: drug targets and mechanisms of action
Session type:
Thematic Poster
Number:
4100
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Xiaoning Zeng (Nanjing, China), Xiaoning Zeng, Yuan Ma, Hao Gu, Yihang Gu, Mao Huang. The effect of oligomeric proanthocyanidin on airway microenvironment in asthma. Eur Respir J 2016; 48: Suppl. 60, 4100
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
From pulmonary gas exchange to the interpretation of arterial blood gases
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Pharmacogenetics in severity of bronchial hyperresponsiveness in asthma
Source: Annual Congress 2013 –Genetic factors in airway development and disease
Year: 2013
Chronic dosing effects of propranolol in asthma
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
The multicomponent nature of difficult asthma
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013
Investigating airway HMGB1 redox state in health and asthma
Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology
Year: 2014
The effect of inhaled ciclesonide on airway blood flow
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Autoreactivity in patients with combined COPD and asthma phenotype
Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma
Year: 2014
Tiotropium for uncontrolled asthma (a meta-analysis)
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Lung specific induction of Wnt-1 has a prophylactic and therapeutic effect on the development of an allergic airway disease
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013
Characterisation of asthma patients with persistent airflow obstruction
Source: International Congress 2016 – Clinical studies in asthma and immunology
Year: 2016
Preventative administration of IL-27 improves airway inflammation of ovalbumin –induced asthma mice model via both STAT1 and GADD45γ/p38MAPK pathways
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
Induced sputum lipid mediators in severe asthma
Source: International Congress 2016 – Translational studies in lung disease
Year: 2016
Characteristics of the adult corticosteroid-dependent severe asthma in UBIOPRED consortium
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014
Vitamin D and airway obstruction in an urban Irish asthmatic population
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
T
H
2 specific biomarker profile determines steroid responsiveness in severe asthma
Source: Annual Congress 2013 –Biomarkers in asthma and COPD
Year: 2013
An extensive function evaluation in severe asthma with airflow limitation
Source: International Congress 2014 – Asthma: still a heterogeneous condition!
Year: 2014
Effect of roflumilast on airway remodeling in a murine model of chronic asthma
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015
Investigating the role of BAFF in murine models of allergic asthma
Source: International Congress 2014 – Paediatric asthma: markers and molecules
Year: 2014
Phenotypic characteristics of asthma with small airways involvement
Source: International Congress 2016 – Notable abstracts on clinical problems related to asthma
Year: 2016
The impact of bacterial lysate on asthma prevention in mouse and its mechanism
Source: International Congress 2014 – Paediatric asthma: markers and molecules
Year: 2014
ADEPT-derived, U-BIOPRED validated asthma clinical clusters with Th2 and non-Th2 phenotypes
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept